Hikal (524735) Stock Overview
Manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, biotechnology, life sciences, animal health, crop protection, and specialty chemicals indusries. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 2/6 |
524735 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Hikal Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹181.40 |
| 52 Week High | ₹386.00 |
| 52 Week Low | ₹145.95 |
| Beta | 0.57 |
| 1 Month Change | -13.99% |
| 3 Month Change | 1.11% |
| 1 Year Change | -51.81% |
| 3 Year Change | -42.59% |
| 5 Year Change | -62.07% |
| Change since IPO | 17,645.71% |
Recent News & Updates
Narrative Update • Jun 04
524735: Board Actions And Dividend Decision Will Support Future Upside Potential
Analysts have kept Hikal's fair value unchanged at ₹320.0 while adjusting underlying assumptions, including a slightly higher discount rate, revised revenue growth and profit margin inputs, and a lower future P/E, which together shape the refreshed price target narrative. What's in the News A board meeting is scheduled for May 27, 2026, at 11:00 IST to review and approve the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026.Narrative Update • Apr 26
524735: Interim Dividend And Stable Assumptions Will Support Future Upside Potential
Analysts have kept their fair value estimate for Hikal steady at ₹320, reflecting unchanged assumptions around discount rate, revenue growth, profit margin, and future P/E multiples. What's in the News A board meeting is scheduled on February 11, 2026 to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, and to consider an interim dividend on equity shares for FY 2025-26 (company filing).Narrative Update • Apr 12
524735: Interim Dividend And Steady Assumptions Will Support Bullish Upside Potential
Analysts have maintained their fair value estimate for Hikal at ₹320, citing essentially unchanged assumptions around discount rate, revenue growth, profit margin, and future P/E. This keeps their overall price target view steady.Recent updates
Narrative Update • Jun 04
524735: Board Actions And Dividend Decision Will Support Future Upside Potential
Analysts have kept Hikal's fair value unchanged at ₹320.0 while adjusting underlying assumptions, including a slightly higher discount rate, revised revenue growth and profit margin inputs, and a lower future P/E, which together shape the refreshed price target narrative. What's in the News A board meeting is scheduled for May 27, 2026, at 11:00 IST to review and approve the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026.Narrative Update • Apr 26
524735: Interim Dividend And Stable Assumptions Will Support Future Upside Potential
Analysts have kept their fair value estimate for Hikal steady at ₹320, reflecting unchanged assumptions around discount rate, revenue growth, profit margin, and future P/E multiples. What's in the News A board meeting is scheduled on February 11, 2026 to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, and to consider an interim dividend on equity shares for FY 2025-26 (company filing).Narrative Update • Apr 12
524735: Interim Dividend And Steady Assumptions Will Support Bullish Upside Potential
Analysts have maintained their fair value estimate for Hikal at ₹320, citing essentially unchanged assumptions around discount rate, revenue growth, profit margin, and future P/E. This keeps their overall price target view steady.Narrative Update • Mar 28
524735: Interim Dividend And Stable Assumptions Will Support Bullish Upside Potential
Analysts have kept their fair value estimate for Hikal broadly unchanged at around ₹320, reflecting largely steady assumptions on discount rate, revenue growth, profit margin and future P/E, and signaling no meaningful shift in their overall view of the stock. What's in the News A board meeting is scheduled on February 11, 2026 to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (company filing).Narrative Update • Mar 13
524735: Interim Dividend And Stable Outlook Will Support Bullish Upside Potential
Analysts have kept their fair value estimate for Hikal steady at ₹320. This points to largely unchanged assumptions around discount rate, revenue growth, profit margin, and future P/E multiple in their latest price target update.Narrative Update • Feb 26
524735: Interim Dividend And Upcoming Results Will Support Bullish Upside Potential
Analysts have kept their price target on Hikal unchanged at ₹320, reflecting broadly steady views on revenue growth, margins and fair value, with only a small adjustment to the assumed future P/E multiple. What's in the News The Board will meet on February 11, 2026 to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, and to consider an interim dividend for FY 2025-26 (company filing).Narrative Update • Feb 12
524735: Upcoming Results And Interim Dividend Decision Will Support Future Upside
Analysts have lifted their price target on Hikal to ₹320, reflecting updated assumptions around a lower discount rate, faster revenue growth, a slimmer profit margin, and a higher future P/E multiple. What's in the News Board meeting scheduled on Feb 11, 2026 to consider and approve the unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025 (Key Developments).Narrative Update • Jan 05
524735: Stable Margins And Upcoming Results Will Support Future Dividend Upside
Analysts have kept their fair value estimate for Hikal steady at ₹320.0 per share. This reflects unchanged views on growth, margins, discount rate, and future P/E assumptions used in their price target work.Narrative Update • Dec 15
524735: Profitability Will Improve As Stable Margins Support Future Dividend Upside
Analysts have modestly reiterated their outlook on Hikal, keeping the average 12 month price target broadly stable around ₹320 per share, as unchanged growth, margin, and valuation assumptions continue to support a steady fair value profile. What's in the News Board meeting scheduled for November 13, 2025, to review and approve standalone and consolidated unaudited financial results for Q2 and H1 FY2025 (company filing) Shareholders at the 37th AGM on September 23, 2025, approved a final dividend of INR 0.80 per equity share of INR 2, taking the total FY2024-25 dividend to INR 1.40 per share (AGM resolution) Valuation Changes Fair Value: Unchanged at approximately ₹320 per share, indicating a stable assessment of intrinsic value.Narrative Update • Nov 30
524735: Profitability Will Improve As Margins Recover And Regulatory Risks Fade
Analysts have raised their price target for Hikal to ₹320.00, citing improved forecasts for revenue growth and profit margin in addition to a stronger outlook for future profitability. What's in the News A board meeting is scheduled for November 13, 2025, to approve unaudited financial results for the second quarter and half year ended September 30, 2025 (Key Developments).Narrative Update • Nov 15
524735: Future Margins Will Recover Following Regulatory Facility Improvements
Narrative Update: Hikal Analyst Price Target Adjustment Analysts have decreased their fair value estimate for Hikal from ₹390 to ₹320 due to revised expectations for revenue decline and lower profit margins. What's in the News The United States FDA issued a warning letter to Hikal's drug manufacturing facility in Karnataka following an inspection in February 2025.Narrative Update • Sep 05
Global Supply Chain Diversification Will Unlock Indian CRAMS Potential
As both net profit margin and consensus revenue growth forecasts for Hikal remained stable, analysts have maintained their fair value estimate with the price target unchanged at ₹390.00. What's in the News Hikal's Board of Directors will meet to consider and approve the standalone and consolidated unaudited financial results for the quarter ended June 30, 2025.
New Narrative • Feb 09
New Panoli Facility And Global Expansions Will Strengthen Operations Over Next 2-3 Years
Strategic focus on operating leverage and product mix is set to improve net margins and revenue diversification.Shareholder Returns
| 524735 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -5.5% | 1.2% | -0.7% |
| 1Y | -51.8% | 6.7% | -4.3% |
Return vs Industry: 524735 underperformed the Indian Pharmaceuticals industry which returned 6.5% over the past year.
Return vs Market: 524735 underperformed the Indian Market which returned -5.1% over the past year.
Price Volatility
| 524735 volatility | |
|---|---|
| 524735 Average Weekly Movement | 7.7% |
| Pharmaceuticals Industry Average Movement | 7.1% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in IN Market | 10.2% |
| 10% least volatile stocks in IN Market | 4.7% |
Stable Share Price: 524735 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 524735's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 2,062 | Sameer Hiremath | www.hikal.com |
Hikal Limited, together with its subsidiaries, manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, biotechnology, life sciences, animal health, crop protection, and specialty chemicals indusries. It operates through two segments, Pharmaceuticals and Crop Protection. The company also manufactures pesticides and herbicides, which include diuron tech, temephos tech, thiacloprid tech, clothianidin tech, dichloroaniline, N-bromosuccinimide, prothioconazole technical, trifloxystrobin technical, and BIT.
Hikal Limited Fundamentals Summary
| 524735 fundamental statistics | |
|---|---|
| Market cap | ₹22.37b |
| Earnings (TTM) | -₹488.00m |
| Revenue (TTM) | ₹17.13b |
1.3x
P/S Ratio-45.8x
P/E RatioIs 524735 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 524735 income statement (TTM) | |
|---|---|
| Revenue | ₹17.13b |
| Cost of Revenue | ₹7.62b |
| Gross Profit | ₹9.51b |
| Other Expenses | ₹10.00b |
| Earnings | -₹488.00m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.96 |
| Gross Margin | 55.52% |
| Net Profit Margin | -2.85% |
| Debt/Equity Ratio | 56.8% |
How did 524735 perform over the long term?
See historical performance and comparisonDividends
0.3%
Current Dividend Yield-15%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/09 07:28 |
| End of Day Share Price | 2026/06/09 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Hikal Limited is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Kameswari V. S. Chavali | FirstCall Research |